CVS Health stock faces 2028 split after stronger quarterly results

Published on 11/09/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock is preparing for a major structural reset after management announced plans to create two focused public companies. Stronger quarterly results support the move.

Key developments for investors

CVS Health plans to separate its healthcare solutions and retail pharmacy operations into two publicly traded companies.
Third-quarter revenue rose year over year, while adjusted earnings increased and cash generation strengthened.
Management raised its 2026 adjusted earnings and operating cash flow outlook but retained a cautious view on medical costs and macroeconomic risks.

CVS Health Corp., US1266501006, Illustration mit AI erstellt.

CVS Health is preparing to split its business into two publicly traded companies after a stronger third quarter and higher full-year guidance. The company announced the plan on Wednesday, November 4, 2026, saying the separation is expected in the first half of 2028 and remains subject to board approval, regulatory filings and other customary conditions.

CVS Health stock traded at 75.54 euros on Lang & Schwarz at 13:02 CET on Monday, November 9, 2026. Investors can follow the real-time quote of CVS Health stock for the latest indication.

Two businesses with separate mandates

According to the CVS Health announcement, the healthcare solutions company will retain Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. David Joyner, the current chairman and chief executive, is slated to lead that business.

The second company, to be named CVS Pharmacy, will include approximately 9,000 retail pharmacies, mail pharmacy operations, MinuteClinic and the Health100 technology services business. Prem Shah, currently CVS Health's group president, is slated to become its chief executive. Existing shareholders are expected to receive shares in both companies when the separation is completed.

CVS Health says the transaction is intended to be tax-free for the company and its shareholders under U.S. federal tax rules. Management also expects both businesses to have investment-grade ratings and strong free cash flow, although the final structure, capital allocation and potential dis-synergies remain important execution issues for investors.

Quarterly earnings improve

CVS Health reported third-quarter revenue of 108.4 billion U.S. dollars, up 5.4 percent from 102.9 billion U.S. dollars a year earlier. Adjusted earnings per share rose to 2.09 U.S. dollars from 1.60 U.S. dollars, while adjusted operating income increased to 4.194 billion U.S. dollars from 3.459 billion U.S. dollars.

The company's earnings release said Health Care Benefits adjusted operating income reached 912 million U.S. dollars, compared with 314 million U.S. dollars in the prior-year quarter. The medical benefit ratio improved to 91.3 percent from 92.8 percent, although elevated medical cost trends remain a risk.

CVS Health raised its 2026 adjusted earnings per share outlook to at least 8.20 U.S. dollars from a previous range of 7.90 to 8.10 U.S. dollars. The company also lifted its operating cash flow forecast to at least 15.5 billion U.S. dollars from at least 11.5 billion U.S. dollars, while projecting revenue of at least 420 billion U.S. dollars.

Execution will shape the valuation

The planned separation gives investors a clearer framework for assessing the insurance and pharmacy operations, but it also creates a long timetable and several milestones. Board approval, the registration statement and tax treatment must be completed before the transaction can close. Until then, CVS Health will operate as one company and must continue meeting its financial targets.

US equities remain the broader market backdrop for CVS Health, with current market reports available through the S&P 500 market theme.

For more coverage, see more news and analyses on CVS Health stock.